Covid19-Unsources

52 bookmarks
Custom sorting
US COVID-19 Vaccines Proven to Cause More Harm than Good Based on Pivotal Clinical Trial Data Analyzed Using the Proper Scientific Endpoint, “All Cause Severe Morbidity” - us-covid19-vaccines-proven-to-cause-more-harm-than-good-based-on-pivotal-clinical-trial-data-analyzed-using-the-proper-scientific--1811.pdf
US COVID-19 Vaccines Proven to Cause More Harm than Good Based on Pivotal Clinical Trial Data Analyzed Using the Proper Scientific Endpoint, “All Cause Severe Morbidity” - us-covid19-vaccines-proven-to-cause-more-harm-than-good-based-on-pivotal-clinical-trial-data-analyzed-using-the-proper-scientific--1811.pdf
Three COVID-19 vaccines in the US have been released for sale by the FDA under Emergency Use Authorization (EUA) based on a clinical trial design employing a surrogate primary endpoint for health, severe infections with COVID-19. This clinical trial design has been proven dangerously misleading. Many fields of medicine, oncology for example, have abandoned the use of disease specific endpoints for the primary endpoint of pivotal clinical trials (cancer deaths for example) and have adopted “all cause mortality or morbidity” as the proper scientific endpoint of a clinical trial. Pivotal clinical trial data from the 3 marketed COVID-19 vaccines was reanalyzed using “all cause severe morbidity", a scientific measure of health, as the primary endpoint. “All cause severe morbidity” in the treatment group and control group was calculated by adding all severe events reported in the clinical trials. Severe events included both severe infections with COVID-19 and all other severe adverse events in the treatment arm and control arm respectively. This analysis gives reduction in severe COVID-19 infections the same weight as adverse events of equivalent severity. Results prove that none of the vaccines provide a health benefit and all pivotal trials show a statically significant increase in “all cause severe morbidity" in the vaccinated group compared to the placebo group. The Moderna immunized group suffered 3,042 more severe events than the control group (p=0.00001). The Pfizer data was grossly incomplete but data provided showed the vaccination group suffered 90 more severe events than the control group (p=0.000014), when only including “unsolicited” adverse events. The Janssen immunized group suffered 264 more severe events than the control group (p=0.00001). These findings contrast the manufacturers’ inappropriate surrogate endpoints: Janssen claims that their vaccine prevents 6 cases of severe COVD-19 requiring medical attention out of 19,630 immunized; Pfizer claims their vaccine prevents 8 cases of severe COVID-19 out of 21,720 immunized; Moderna claims its vaccine prevents 30 cases of severe COVID-19 out of 15,210 immunized. Based on this data it is all but a certainty that mass COVID-19 immunization is hurting the health of the population in general. Scientific principles dictate that the mass immunization with COVID-19 vaccines must be halted immediately because we face a looming vaccine induced public health catastrophe.
·scivisionpub.com·
US COVID-19 Vaccines Proven to Cause More Harm than Good Based on Pivotal Clinical Trial Data Analyzed Using the Proper Scientific Endpoint, “All Cause Severe Morbidity” - us-covid19-vaccines-proven-to-cause-more-harm-than-good-based-on-pivotal-clinical-trial-data-analyzed-using-the-proper-scientific--1811.pdf
The Foegen effect: A mechanism by which facemasks... : Medicine
The Foegen effect: A mechanism by which facemasks... : Medicine
med to determine whether mandatory mask use influenced the case fatality rate in Kansas, USA between August 1st and October 15th 2020. This study applied secondary data on case updates, mask mandates, and demographic status related to Kansas State, USA. A parallelization analysis based on county-level data was conducted on these data. Results were controlled by performing multiple sensitivity analyses and a negative control. A parallelization analysis based on county-level data showed that in Kansas, counties with mask mandate had significantly higher case fatality rates than counties without mask mandate, with a risk ratio of 1.85 (95% confidence interval [95% CI]: 1.51–2.10) for COVID-19-related deaths. Even after adjusting for the number of “protected persons,” that is, the number of persons who were not infected in the mask-mandated group compared to the no-mask group, the risk ratio remained significantly high at 1.52 (95% CI: 1.24–1.72). By analyzing the excess mortality in Kansas, this study determines that over 95% of this effect can solely be attributed to COVID-19. These findings suggest that mask use might pose a yet unknown threat to the user instead of protecting them, making mask mandates a debatable epidemiologic intervention. The cause of this trend is explained herein using the “Foegen effect” theory; that is, deep re-inhalation of hypercondensed droplets or pure virions caught in facemasks as droplets can worsen prognosis and might be linked to long-term effects of COVID-19 infection. While the “Foegen effect” is proven in vivo in an animal model, further research is needed to fully understand it....
·journals.lww.com·
The Foegen effect: A mechanism by which facemasks... : Medicine
Viren sind nicht das Problem-bleiben Sie besonnen!
Viren sind nicht das Problem-bleiben Sie besonnen!
Vimeo hat meinen Kanal mit allen Beiträgen gelöscht. Nach LinkedIn und Youtube ist das eine weitere Steigerung der Zensur. Ich bin zu Odyssee gewechselt. Schande über VIMEO. Aber hier ist das gelöschte Video mit meinem Grußwort an die Spaziergänger.
·wodarg.com·
Viren sind nicht das Problem-bleiben Sie besonnen!
Does Influenza Transmission Occur from Asymptomatic Infection or Prior to Symptom Onset?
Does Influenza Transmission Occur from Asymptomatic Infection or Prior to Symptom Onset?
A better understanding of transmission dynamics is essential in influenza pandemic planning. If a substantial proportion of transmissions were to occur during the presymptomatic phase or from asymptomatic individuals, then infection control measures such ...
·ncbi.nlm.nih.gov·
Does Influenza Transmission Occur from Asymptomatic Infection or Prior to Symptom Onset?
Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection
Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection
Ivermectin is an antiparasitic drug being investigated for repurposing to SARS-CoV-2. In-vitro, ivermectin showed limited antiviral activity and a COVID-19 animal model demonstrated pathological benefits but no effect on viral RNA. This meta-analysis investigated ivermectin in 18 randomized cl...
·researchsquare.com·
Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection
SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19 | Journal of Hematology & Oncology | Full Text
SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19 | Journal of Hematology & Oncology | Full Text
Background Critically ill patients diagnosed with COVID-19 may develop a pro-thrombotic state that places them at a dramatically increased lethal risk. Although platelet activation is critical for thrombosis and is responsible for the thrombotic events and cardiovascular complications, the role of platelets in the pathogenesis of COVID-19 remains unclear. Methods Using platelets from healthy volunteers, non-COVID-19 and COVID-19 patients, as well as wild-type and hACE2 transgenic mice, we evaluated the changes in platelet and coagulation parameters in COVID-19 patients. We investigated ACE2 expression and direct effect of SARS-CoV-2 virus on platelets by RT-PCR, flow cytometry, Western blot, immunofluorescence, and platelet functional studies in vitro, FeCl3-induced thrombus formation in vivo, and thrombus formation under flow conditions ex vivo. Results We demonstrated that COVID-19 patients present with increased mean platelet volume (MPV) and platelet hyperactivity, which correlated with a decrease in overall platelet count. Detectable SARS-CoV-2 RNA in the blood stream was associated with platelet hyperactivity in critically ill patients. Platelets expressed ACE2, a host cell receptor for SARS-CoV-2, and TMPRSS2, a serine protease for Spike protein priming. SARS-CoV-2 and its Spike protein directly enhanced platelet activation such as platelet aggregation, PAC-1 binding, CD62P expression, α granule secretion, dense granule release, platelet spreading, and clot retraction in vitro, and thereby Spike protein enhanced thrombosis formation in wild-type mice transfused with hACE2 transgenic platelets, but this was not observed in animals transfused with wild-type platelets in vivo. Further, we provided evidence suggesting that the MAPK pathway, downstream of ACE2, mediates the potentiating role of SARS-CoV-2 on platelet activation, and that platelet ACE2 expression decreases following SARS-COV-2 stimulation. SARS-CoV-2 and its Spike protein directly stimulated platelets to facilitate the release of coagulation factors, the secretion of inflammatory factors, and the formation of leukocyte–platelet aggregates. Recombinant human ACE2 protein and anti-Spike monoclonal antibody could inhibit SARS-CoV-2 Spike protein-induced platelet activation. Conclusions Our findings uncovered a novel function of SARS-CoV-2 on platelet activation via binding of Spike to ACE2. SARS-CoV-2-induced platelet activation may participate in thrombus formation and inflammatory responses in COVID-19 patients.
·jhoonline.biomedcentral.com·
SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19 | Journal of Hematology & Oncology | Full Text
Debatte über SARS-CoV-2-Ursprung - Neue Hinweise für Labor-Genese?
Debatte über SARS-CoV-2-Ursprung - Neue Hinweise für Labor-Genese?
Woher stammt das Coronavirus? Aus der Natur oder aus einem Forschungslabor? Auf Einladung des Wissenschaftsmagazin "Science" diskutierten nun vier Experten mit unterschiedlichen Ansichten die Ursprungstheorien. Thematisiert wurden dabei auch neue Studien und neu aufgetauchte Dokumente.
·deutschlandfunk.de·
Debatte über SARS-CoV-2-Ursprung - Neue Hinweise für Labor-Genese?
Vitamin D Überdosierung: Die wichtigsten Fragen und Antworten
Vitamin D Überdosierung: Die wichtigsten Fragen und Antworten
Rund 80% der deutschen Bevölkerung leidet heutzutage unter einem Vitamin D Mangel. Gerade wegen solchen Aussagen entscheiden sich immer mehr Menschen dazu, selbständig Vitamin D Präparate zu sich zu nehmen, um einen Mangel auszugleichen oder vorzubeugen. Eine unbedachte Einnahme ohne […]
·arzneimittelfakten.de·
Vitamin D Überdosierung: Die wichtigsten Fragen und Antworten
Vitamin D Überdosierung
Vitamin D Überdosierung
Vitamin D Überdosierung tritt erst bei sehr großen Mengen auf. Allerdings kann hochdosiertes Vitamin D zu Mineralstoffmängeln und Verkalkung führen.
·vitamind.net·
Vitamin D Überdosierung
Serum 25-hydroxyvitamin D and cognitive decline in the very old: the Newcastle 85+ Study
Serum 25-hydroxyvitamin D and cognitive decline in the very old: the Newcastle 85+ Study
Studies investigating the association between 25-hydroxyvitamin D [25(OH)D] and cognition in the very old (85+) are lacking.Cross-sectional (baseline) and prospective data (up to 3 years follow-up) from 775 participants in the Newcastle 85+ Study ...
·ncbi.nlm.nih.gov·
Serum 25-hydroxyvitamin D and cognitive decline in the very old: the Newcastle 85+ Study
Four SARS-CoV-2 vaccines induce quantitatively different antibody responses against SARS-CoV-2 variants
Four SARS-CoV-2 vaccines induce quantitatively different antibody responses against SARS-CoV-2 variants
Emerging and future SARS-CoV-2 variants may jeopardize the effectiveness of vaccination campaigns. We performed a head-to-head comparison of the ability of sera from individuals vaccinated with either one of four vaccines (BNT162b2, mRNA-1273, AZD1222 or Ad26.COV2.S) to recognize and neutralize the four SARS-CoV-2 variants of concern (VOCs; Alpha, Beta, Gamma and Delta). Four weeks after completing the vaccination series, SARS-CoV-2 wild-type neutralizing antibody titers were highest in recipients of BNT162b2 and mRNA-1273 (median titers of 1891 and 3061, respectively), and substantially lower in those vaccinated with the adenovirus vector-based vaccines AZD1222 and Ad26.COV2.S (median titers of 241 and 119, respectively). VOCs neutralization was reduced in all vaccine groups, with the largest (5.8-fold) reduction in neutralization being observed against the Beta variant. Overall, the mRNA vaccines appear superior to adenovirus vector-based vaccines in inducing neutralizing antibodies against VOCs four weeks after the final vaccination. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement the Netherlands Organization for Scientific Research (NWO) ZonMw (no. 10430022010023 no. 10150062010002 no. 91818627) the Bill & Melinda Gates Foundation (no. INV-002022 no. INV008818 no. INV-024617) the Amsterdam UMC through the AMC Fellowship and the Corona Research Fund the European Unions Horizon 2020 program (no. 101003589). ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The S3 study, the COSCA study and the RECoVERED study were approved by the medical ethical review board of the Amsterdam University Medical Centers (NL73478.029.20, NL73281.018.20 and NL73759.018.20, respectively). All participants provided written informed consent. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes All data are available in the main text or supplementary materials. Reagents used in this study are available upon reasonable request under an MTA with Amsterdam UMC.
·medrxiv.org·
Four SARS-CoV-2 vaccines induce quantitatively different antibody responses against SARS-CoV-2 variants
2021
2021
·medrxiv.org·
2021
Divergence of delta and beta variants and SARS-CoV-2 evolved in prolonged infection into distinct serological phenotypes
Divergence of delta and beta variants and SARS-CoV-2 evolved in prolonged infection into distinct serological phenotypes
SARS-CoV-2 continues to evolve variants of concern (VOC) which escape antibody neutralization and have enhanced transmission. One variant may escape immunity elicited by another, and the delta VOC has been reported to escape beta elicited immunity. Systematic mapping of the serological distance of current and emerging variants will likely guide the design of vaccines which can target all variants. Here we isolated and serologically characterized SARS-CoV-2 which evolved from an ancestral strain in a person with advanced HIV disease and delayed SARS-CoV-2 clearance. This virus showed evolving escape from self antibody neutralization immunity and decreased Pfizer BNT162b2 vaccine neutralization sensitivity. We mapped neutralization of evolved virus and ancestral, beta and delta variant viruses by antibodies elicited by each VOC in SARS-CoV-2 convalescent individuals. Beta virus showed moderate (7-fold) and delta slight escape from neutralizing immunity elicited by ancestral virus infection. In contrast, delta virus had stronger escape from beta elicited immunity (12-fold), and beta virus even stronger escape from delta immunity (34-fold). Evolved virus had 9-fold escape from ancestral immunity, 27-fold escape from delta immunity, but was effectively neutralized by beta immunity. We conclude that beta and delta are serologically distant, further than each is from ancestral, and that virus evolved in prolonged infection during advanced HIV disease is serologically close to beta and far from delta. These results suggest that SARS-CoV-2 is diverging into distinct serological phenotypes and that vaccines tailored to one variant may become vulnerable to infections with another. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This study was supported by the Bill and Melinda Gates award INV-018944 (AS), National Institutes of Health award R01 AI138546 (AS), South African Medical Research Council awards (AS, TdO, PLM) and National Institutes of Health U01 AI151698 (WVV). PLM is supported by the South African Research Chairs Initiative of the Department of Science and Innovation and the NRF (Grant No 9834). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Nasopharyngeal and oropharyngeal swab samples and plasma samples were obtained from hospitalized adults with PCR confirmed SARS-CoV-2 infection who were enrolled in a prospective cohort study approved by the Biomedical Research Ethics Committee at the University of KwaZulu Natal (reference BREC/00001275/2020). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes All data available in the manuscript, GISAID SARS-CoV-2 sequence repository, or upon reasonable request from the authors.
·medrxiv.org·
Divergence of delta and beta variants and SARS-CoV-2 evolved in prolonged infection into distinct serological phenotypes
Waning immunity of the BNT162b2 vaccine: A nationwide study from Israel
Waning immunity of the BNT162b2 vaccine: A nationwide study from Israel
Background Starting December 2020, Israel began a mass vaccination campaign against coronavirus administering the Pfizer BNT162b2 vaccine, which led to a sharp curtailing of the outbreak. After a period with almost no SARS-CoV-2 infections, a resurgent COVID-19 outbreak initiated mid June 2021. Possible reasons for the breakthrough were reduced vaccine effectiveness against the Delta variant, and waning immunity. The aim of this study was to quantify the extent of waning immunity using Israel’s national-database. Methods Data on all PCR positive test results between July 11-31, 2021 of Israeli residents who became fully vaccinated before June 2021 were used in this analysis. Infection rates and severe COVID-19 outcomes were compared between individuals who were vaccinated in different time periods using a Poisson regression, stratifying by age group and adjusting for possible confounding factors. Results The rates of both documented SARS-CoV-2 infections and severe COVID-19 exhibit a statistically significant increase as time from second vaccine dose elapsed. Elderly individuals (60+) who received their second dose in March 2021 were 1.6 (CI: [1.3, 2]) times more protected against infection and 1.7 (CI: [1.0, 2.7]) times more protected against severe COVID-19 compared to those who received their second dose in January 2021. Similar results were found for different age groups. Conclusions These results indicate a strong effect of waning immunity in all age groups after six months. Quantifying the effect of waning immunity on vaccine effectiveness is critical for policy makers worldwide facing the dilemma of administering booster vaccinations. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement No funding. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The study was approved by the Institutional Review Board of the Sheba Medical Center. Helsinki approval number: SMC-8228-21. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes Aggregated data are given in the supplementary information. Personal data cannot be shared due to privacy.
·medrxiv.org·
Waning immunity of the BNT162b2 vaccine: A nationwide study from Israel
(5) Ofra Amir auf Twitter: "A new pre-print of a study showing a detailed analysis of waning immunity in Israel: https://t.co/3OwrnDTpV6 TL/DR: infection rate and severe disease rates both significantly increase with vaccine age (thread)" / Twitter
(5) Ofra Amir auf Twitter: "A new pre-print of a study showing a detailed analysis of waning immunity in Israel: https://t.co/3OwrnDTpV6 TL/DR: infection rate and severe disease rates both significantly increase with vaccine age (thread)" / Twitter
A new pre-print of a study showing a detailed analysis of waning immunity in Israel: https://t.co/3OwrnDTpV6 TL/DR: infection rate and severe disease rates both significantly increase with vaccine age (thread)
·twitter.com·
(5) Ofra Amir auf Twitter: "A new pre-print of a study showing a detailed analysis of waning immunity in Israel: https://t.co/3OwrnDTpV6 TL/DR: infection rate and severe disease rates both significantly increase with vaccine age (thread)" / Twitter
(5) מואיז הקטן ® auf Twitter: "---Severe COVID-19 patients, ages 12-60 in ISRAEL--- . Only 19% of the population are unvaccinated and are responsible for 78% of the severely hospitalized. . Only 2 patients under the age of 20 so without them it is only 15% who are not vaccinated. https://t.co/NX4EQ2uIjg" / Twitter
(5) מואיז הקטן ® auf Twitter: "---Severe COVID-19 patients, ages 12-60 in ISRAEL--- . Only 19% of the population are unvaccinated and are responsible for 78% of the severely hospitalized. . Only 2 patients under the age of 20 so without them it is only 15% who are not vaccinated. https://t.co/NX4EQ2uIjg" / Twitter
---Severe COVID-19 patients, ages 12-60 in ISRAEL--- . Only 19% of the population are unvaccinated and are responsible for 78% of the severely hospitalized. . Only 2 patients under the age of 20 so without them it is only 15% who are not vaccinated. https://t.co/NX4EQ2uIjg
·twitter.com·
(5) מואיז הקטן ® auf Twitter: "---Severe COVID-19 patients, ages 12-60 in ISRAEL--- . Only 19% of the population are unvaccinated and are responsible for 78% of the severely hospitalized. . Only 2 patients under the age of 20 so without them it is only 15% who are not vaccinated. https://t.co/NX4EQ2uIjg" / Twitter
(4) Yair Lewis auf Twitter: "@EricTopol @CellCellPress Adding some context from Israel: 1. The analysis by Israel MoH specifically stated that symptomatic infections weren’t analysed d/t data issues 2. VE for severe disease is 94% after 6m+ in 40-59yo, accdn’g to Israel MoH analysis https://t.co/Tga9vb6Flv" / Twitter
(4) Yair Lewis auf Twitter: "@EricTopol @CellCellPress Adding some context from Israel: 1. The analysis by Israel MoH specifically stated that symptomatic infections weren’t analysed d/t data issues 2. VE for severe disease is 94% after 6m+ in 40-59yo, accdn’g to Israel MoH analysis https://t.co/Tga9vb6Flv" / Twitter
@EricTopol @CellCellPress Adding some context from Israel: 1. The analysis by Israel MoH specifically stated that symptomatic infections weren’t analysed d/t data issues 2. VE for severe disease is 94% after 6m+ in 40-59yo, accdn’g to Israel MoH analysis https://t.co/Tga9vb6Flv
·twitter.com·
(4) Yair Lewis auf Twitter: "@EricTopol @CellCellPress Adding some context from Israel: 1. The analysis by Israel MoH specifically stated that symptomatic infections weren’t analysed d/t data issues 2. VE for severe disease is 94% after 6m+ in 40-59yo, accdn’g to Israel MoH analysis https://t.co/Tga9vb6Flv" / Twitter
Bilanz des PEI: Deutlich mehr Kinder mit Impfreaktion als mit COVID-19-Diagnose im Krankenhaus
Bilanz des PEI: Deutlich mehr Kinder mit Impfreaktion als mit COVID-19-Diagnose im Krankenhaus
Herzentzündungen, Embolien und die ersten Toten: Nach Beginn der Impfkampagne für Kinder und Jugendliche ab zwölf Jahren häufen sich die Verdachtsmeldungen möglicher Impfschäden auch in dieser Altersgruppe. Das geht aus dem neuen Bericht des Paul-Ehrlich-Instituts bis Ende August hervor. Und wahrscheinlich ist das nur die Spitze des Eisbergs.
·de.rt.com·
Bilanz des PEI: Deutlich mehr Kinder mit Impfreaktion als mit COVID-19-Diagnose im Krankenhaus